Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16861443 | 1.00 | TUBB1 (0.33) | TUBB1PTGS1AKR1C3 | |
| SCHEMBL16862667 | 1.00 | TUBB1 (0.33) | TUBB1PTGS1AKR1C3 | |
| SCHEMBL22643755 | 1.00 | TUBB1 (0.33) | TUBB1PTGS1AKR1C3 | |
| SCHEMBL5578335 | 1.00 | TUBB1 (0.33) | TUBB1PTGS1AKR1C3 | |
| Hydrochloric Acid SCHEMBL6669635 | 0.98 | TUBB1 (0.33) | TUBB1 | |
| Hydrochloric Acid SCHEMBL6669625 | 0.98 | TUBB1 (0.33) | TUBB1 | |
| Trifluoroacetic Acid SCHEMBL6673944 | 0.89 | TUBB1 (0.32) | TUBB1 | |
| Trifluoroacetic Acid SCHEMBL6673938 | 0.89 | TUBB1 (0.32) | TUBB1 | |
| SCHEMBL21086708 | 0.84 | KISS1R (0.32) | — | |
| SCHEMBL1537984 | 0.79 | TUBB1 (0.32) | TUBB1PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004047615-A2 | HEMIASTERLIN AFFINITY PROBES AND THEIR USES | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | TUBA1C, TUBB1, TUBB | TUBB1 2/4885PTGS1 2855/4885AKR1C3 2159/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885PTGS1 330/4885AKR1C3 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.